<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1684-1824</journal-id>
<journal-title><![CDATA[Revista Médica Electrónica]]></journal-title>
<abbrev-journal-title><![CDATA[Rev.Med.Electrón.]]></abbrev-journal-title>
<issn>1684-1824</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Ciencias Médicas de Matanzas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1684-18242018000601875</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Impacto del uso de esteroides en el tratamiento de los pacientes con neumonía grave adquirida en la comunidad]]></article-title>
<article-title xml:lang="en"><![CDATA[The impact of steroids usage in the treatment of patients with severe community-acquired pneumonia]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García Álvarez]]></surname>
<given-names><![CDATA[Pedro Julio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez Huguet]]></surname>
<given-names><![CDATA[Marllelis]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Docente Militar Dr. Carlos J. Finlay  ]]></institution>
<addr-line><![CDATA[ La Habana]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Docente Amalia Simoni  ]]></institution>
<addr-line><![CDATA[ Camagüey]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2018</year>
</pub-date>
<volume>40</volume>
<numero>6</numero>
<fpage>1875</fpage>
<lpage>1889</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1684-18242018000601875&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1684-18242018000601875&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1684-18242018000601875&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción: a neumonía adquirida en la comunidad constituye un importante problema de salud a nivel global. Es la tercera causa de muerte globalmente. EL mejor tratamiento para estos pacientes todavía no está bien establecido.  Objetivo:  evaluar el impacto en la mortalidad del uso de los esteroides por vía sistémica en pacientes con neumonía grave adquirida en la comunidad así como relacionarlos con el valor del leucograma, creatinina y presión arterial de oxígeno.  Materiales y métodos:  estudio analítico longitudinal prospectivo, con los pacientes ingresados en la Unidad de Cuidados Intensivos Emergentes por neumonía adquirida en la comunidad del Hospital Militar Dr. Carlos J. Finlay, de enero - junio de 2017. El universo de 85 pacientes, muestra de 48 que fueron divididos aleatoriamente en 2 grupos. Ambos grupos recibieron la misma combinación de fármacos y al primer grupo se le administro Hidrocortisona 4 mg/ Kg/ día por 5 días y al segundo no se le administro ningún esteroide.  Resultados: edades 80 ±11 años y 77 ±11 años. 20 pacientes vivos que recibieron esteroides y 14 fallecidos que no lo recibieron. X2=0,04. Las medias de los leucogramas fueron Grupo 1=17 y Grupo 2=13 con p=0,16 .En la presión arterial de oxigeno Grupo 1=102 y Grupo 2=95 con p=0,77. El valor de la creatinina Grupo 1=156 y Grupo 2=177 con p=0, 323.  Conclusiones:  el uso de esteroides en pacientes graves con NAC puede reducir la mortalidad a corto plazo sin diferencias significativas en los parámetros de oxigenación, de la función renal ni de los leucocitos.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  community-acquired pneumonia is an important health problem around the world. It is the third cause of death in the world. The best treatment for these patients has not been still clearly stablished.  Objective:  to assess the impact of the use of steroids by systemic way on the mortality of patients with community-acquired pneumonia and to establish the relationship the leukogramm, creatinine and oxygen arterial pressure (presión arterial de oxígeno) values.  Materials and methods:  prospective, longitudinal, analytic study of the patients with community-acquired pneumonia who entered the intensive care unit of the Military Hospital &#8220;Dr. Carlos J. Finlay&#8221; in the period January-June 2017. In a universe of 85 patients, the sample was formed by 48 patients randomly divided in two groups. Both groups receive the same drugs combination; the first group was given Hydrocortisone 4 mg/kg/day for five days while the second one was not administered steroid at all.  Results:  patients were aged 80±11 years and 77±11 years. 20 patients who stayed alive took steroids, and 14 who did not take them died. X2=0.04. The average leucogramma was Group 1=17 and Group 2=13, with p=0.77. The oxygen arterial pressure was Group 1=102 and Group 2=95. Creatinine value was Group 1=156 and Group2=177 with p=0.323.  Conclusions:  The steroids use in patients with community-acquired pneumonia could reduce mortality at a short time, without significant differences in the oxygenation, renal functioning or leucocytes parameters.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[neumonía adquirida en la comunidad]]></kwd>
<kwd lng="es"><![CDATA[mortalidad]]></kwd>
<kwd lng="es"><![CDATA[esteroides.]]></kwd>
<kwd lng="en"><![CDATA[community-acquired pneumonia]]></kwd>
<kwd lng="en"><![CDATA[mortality]]></kwd>
<kwd lng="en"><![CDATA[steorids.]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sharma]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sneath]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Cheng]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Friedman]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Community-acquired syndromes causing morbidity and mortality in Australia]]></article-title>
<source><![CDATA[Commun Dis Intell Q Rep]]></source>
<year>2017</year>
<volume>41</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>E49-57</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caggiano]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ullmann]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[De Vitis]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factors That Negatively Affect the Prognosis of Pediatric Community-Acquired Pneumonia in District Hospital in Tanzania]]></article-title>
<source><![CDATA[Int J Mol Sci]]></source>
<year>2017</year>
<volume>18</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Blum]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Nigro]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Winzeler]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Corticosteroid treatment for community-acquired pneumonia--the STEP trial: study protocol for a randomized controlled trial]]></article-title>
<source><![CDATA[Trials]]></source>
<year>2014</year>
<volume>15</volume>
<page-range>257</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sparham]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Charles]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Controversies in diagnosis and management of community-acquired pneumonia]]></article-title>
<source><![CDATA[Med J Aust]]></source>
<year>2017</year>
<volume>206</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>316-9</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="book">
<source><![CDATA[Estadisticas de Salud. Anuario estadistico de la salud]]></source>
<year>2013</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[Estadisticas de Salud]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vardakas]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Trigkidis]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Falagas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fluoroquinolones or macrolides in combination with &#946;-lactams in adult patients hospitalized with community acquired pneumonia: a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Clin Microbiol Infect]]></source>
<year>2017</year>
<volume>23</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>234-41</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Jang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hong]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Relationship between serum vitamin D concentrations and clinical outcome of community-acquired pneumonia]]></article-title>
<source><![CDATA[Int J Tuberc Lung Dis]]></source>
<year>2015</year>
<volume>19</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>729-34</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Papi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Dalvi]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The EFFECT trial: evaluating exacerbations, biomarkers, and safety outcomes with two dose levels of fluticasone propionate/formoterol in COPD]]></article-title>
<source><![CDATA[Int J Chron Obstruct Pulmon Dis]]></source>
<year>2015</year>
<volume>10</volume>
<page-range>2431-8</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment for hospitalized patients with severe community-acquired pneumonia]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2015</year>
<volume>313</volume>
<numero>21</numero>
<issue>21</issue>
<page-range>2184-5</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sibila]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2015</year>
<volume>313</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>677-86</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mayor]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Corticosteroids reduce treatment failure in severe community acquired pneumonia, trial shows]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2015</year>
<volume>350</volume>
<page-range>h894</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vestjens]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Spoorenberg]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Rijkers]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antipyretic effect of dexamethasone in community-acquired pneumonia]]></article-title>
<source><![CDATA[Eur Respir J]]></source>
<year>2015</year>
<volume>46</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>570-3</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pepper]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment for hospitalized patients with severe community-acquired pneumonia]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2015</year>
<volume>313</volume>
<numero>21</numero>
<issue>21</issue>
<page-range>2184</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mayor]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Corticosteroids reduce treatment failure in severe community acquired pneumonia, trial shows]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2015</year>
<volume>350</volume>
<page-range>h894</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baskar]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Sum]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lim]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prednisone for community-acquired pneumonia: not yet time]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2015</year>
<volume>386</volume>
<numero>9992</numero>
<issue>9992</issue>
<page-range>431</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Meijvis]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hardeman]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Remmelts]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2011</year>
<volume>377</volume>
<numero>9782</numero>
<issue>9782</issue>
<page-range>2023-30</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Siemieniuk]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Guyatt]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Corticosteroids in the treatment of community-acquired pneumonia: an evidence summary]]></article-title>
<source><![CDATA[Pol Arch Med Wewn]]></source>
<year>2015</year>
<volume>125</volume>
<numero>7-8</numero>
<issue>7-8</issue>
<page-range>570-5</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mandell]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Community-acquired pneumonia: An overview]]></article-title>
<source><![CDATA[Postgrad Med]]></source>
<year>2015</year>
<volume>127</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>607-15</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Blum]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Nigro]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Winzeler]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Corticosteroid treatment for community-acquired pneumonia-the STEP trial: study protocol for a randomized controlled trial]]></article-title>
<source><![CDATA[Trials]]></source>
<year>2014</year>
<volume>15</volume>
<page-range>257</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zürcher]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Including corticoids in the treatment of community-acquired pneumonia?]]></article-title>
<source><![CDATA[Rev Med Suisse]]></source>
<year>2015</year>
<volume>11</volume>
<numero>465</numero>
<issue>465</issue>
<page-range>625</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pommer]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Better control of severe community-acquired pneumonia through treatment with cortisone]]></article-title>
<source><![CDATA[Dtsch Med Wochenschr]]></source>
<year>2015</year>
<volume>140</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>559</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rasche]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Nitschmann]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Community-acquired pneumonia]]></article-title>
<source><![CDATA[New treatment concepts.Internist (Berl)]]></source>
<year>2015</year>
<volume>56</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1458-62</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Blum]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Nigro]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Briel]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2015</year>
<volume>385</volume>
<numero>9977</numero>
<issue>9977</issue>
<page-range>1511-8</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stolberg]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[McCubbrey]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Freeman]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Glucocorticoid-Augmented Efferocytosis Inhibits Pulmonary Pneumococcal Clearance in Mice by Reducing Alveolar Macrophage Bactericidal Function]]></article-title>
<source><![CDATA[J Immunol]]></source>
<year>2015</year>
<volume>195</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>174-84</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lara Aguayo]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Rojas Amezcua]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fuente Martos]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neumonía adquirida en la comunidad]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Vasserot Vargas]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<source><![CDATA[Tratado de medicina intensiva]]></source>
<year>2017</year>
<page-range>618-24</page-range><publisher-loc><![CDATA[España ]]></publisher-loc>
<publisher-name><![CDATA[Elsevier]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ruiz Ruano]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Redondo Orts]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez Villares]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Farmacología inmunosupresora]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Vasserot Vargas]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<source><![CDATA[Tratado de Medicina Intensiva]]></source>
<year>2017</year>
<page-range>935-40</page-range><publisher-loc><![CDATA[España ]]></publisher-loc>
<publisher-name><![CDATA[Elsevier]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tian]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Jiang]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sun]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The indications for glucocorticoids in treating community-acquired pneumonia in adults: a meta-analysis]]></article-title>
<source><![CDATA[Zhonghua Jie He He Hu Xi Za Zhi]]></source>
<year>2016</year>
<volume>39</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>280-5</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
